top of page
Home: Welcome
Cellfinity Closeup_Final_.jpg

Pioneering Massive Directed
Evolution to Unlock Infinite
Potential of Cell Therapy

Home: About Us
Cellfinity Image_7-14.jpg


Pioneering Directed Evolution of Immune Cells

To revolutionize cell therapy, we develop proprietary next-generation technologies that opens near-infinite   
possibilities of cell therapy by:







We welcome you to join our mission of treating cancer with innovative science.

Get in touch today to learn more about the Cellinfinity Bio story.


Harness the power of natural selection to identify most robust genetic modifications that optimize immune cells' potency, persistence, infiltration


Engineer & create potent immune cells with technologies that are robust, reproducible, and highly efficient.

Create Diverse Pool

Generate large collection/library

of thousands of therapeutic

immune cells, each with unique

gain-of-function and/or loss-of-function gene modification.

Home: Our Technology
Pipetting Samples_edited.jpg


Science Lab
Calm Woman

We use directed evolution experiments to identify genetic modifications and CAR constructs that substantially improve engineered immune cell function against cancer. 

​These discoveries allow development of first-in-class (with proprietary gene modifications and unique targets/CARs) and best-in-class (with proprietary modifications and optimized CARs) products.

​Our pipeline consists of genetically engineered T cell, NK cell and other immune cells that have potent activity against multiple malignancies including solid tumors. 

Management Team

Cellinfinity Bio is led by seasoned industry veterans, scientists, and business leaders.


Premal Patel, MD/PHD

Chief Executive Officer

  • Over 15 years of oncology drug development

  • Former Chief Medical Officer at Lyell Immunopharma and at eFFECTOR Therapeutics

  • SVP Juno Therapeutics (Head, Early Clinical Development)

  • VP Pfizer (Head of Immuno-Onc Early Clinical Dev, allogeneic CARTs licensed to Allogene)

  • Sr Director Genentech, Research and Early Clinical Development


Philip Kong, PHD

Chief Operating Officer

  • Former founder and CSO of Statera Therapeutics

  • 7+ years of immunology R&D

  • 4+ years of life sciences investment at hedge funds

  • Former strategy consultant at Flagship Pioneering, Naveos Biopharma, and Nucleate Bio


Sidi Chen, PHD


  • Founder of Cellinfinity Bio

  • Associate Professor at Yale University and group leader at Yale University

  • Prolific publication and invention records in gene editing and immunotherapy

Margo_Final .jpg

Margo Roberts, PHD

Chief Scientific Advisor 

  • Superb track records in cell therapy

  • Former chief scientific officer (CSO) at Lyell Immunopharma and Kite Pharma. Led multiple cell therapy programs to clinic.

  • Endpoints News’ Top 20 Women Leaders in Biopharma 2020.


Greg Naeve, PHD

Chief Business Officer

  • Biotech/Pharma Executive and Entrepreneur with strong BD records and expertise

  • President, Parallax Strategic Advisors, Chief Business Officer, Bellicum Pharmaceuticals

  • Prior R&D Lead, ImmunoOncology & Cell Therapy, Pfizer

Mike Green 7.25 .jpg

Michael Green, MBA

Chief Financial Officer

  • 25+ years of financial & operational executive leadership roles within pharma, biotech, medical device, service, technology, and manufacturing industries

  • Held CFO level roles for pre-revenue start-ups, middle market companies, and large public entities

  • Expertise in turnaround, cost reduction, capital raise, debt structuring, M&A transactions, financial modeling, accounting, cash management, and strategic planning

Hands on Computer Keyboard


Dai, X., Park, J.J., Du, Y. et al. Massively parallel knock-in engineering of human T cells. (2023).

Nature Biotechnology 2023. PDF

Ye, L., Park, J. J., Peng, L., Yang, Q., Chow, R. D., Dong, M. B., … & Chen, S. (2022).

A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy.

Cell Metabolism 2022. doi: 10.1016/j.cmet.2022.02.009 PDF

Dai X*, Park JJ*, Du Y, Kim HR, Wang G, Errami Y, Chen S. One-step generation of modular CAR-T with AAV-Cpf1.

Nature Methods 2019. doi: 10.1038/s41592-019-0329. PDF

Home: Pub

Alex Yemelyanov


Hemant Mishra

Narges Tafreshi

Carolyn Kaya

Jun Liu


Roger Liu

Geeta Ram

Manuel Mohr

Stylianos Kosmidis

Venkata 'Sekhar' Boddupalli


Our Scientists



“I’m delighted to be a part of Cellinfinity Bio's exciting and innovative approach to cell therapy,

and I look forward to working together on the development of game-changing immunotherapies

for patients.”

Margo_Final .jpg

Margo Roberts

Chief Scientific Advisor

Former Chief Scientific Officer, Lyell Immunopharma & Kite Pharma

All interested applicants should submit their resume and cover letter to

Note to recruitment agencies: Cellinfinity Bio does not accept unsolicited resumes from recruitment agencies. Cellinfinity Bio is not responsible for any fees related to resumes that have been distributed without agreement.

Home: Contact

Contact Us

520 West Campus Drive, West Haven, CT 06516

930 Brittan Ave, San Carlos, CA 94070

For business inquiries, please contact us at
bottom of page